235 related articles for article (PubMed ID: 30866497)
1. Aberrant
Bjerre MT; Strand SH; Nørgaard M; Kristensen H; Rasmussen AK; Mortensen MM; Fredsøe J; Mouritzen P; Ulhøi B; Ørntoft T; Borre M; Sørensen KD
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866497
[TBL] [Abstract][Full Text] [Related]
2. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential.
Bjerre MT; Nørgaard M; Larsen OH; Jensen SØ; Strand SH; Østergren P; Fode M; Fredsøe J; Ulhøi BP; Mortensen MM; Jensen JB; Borre M; Sørensen KD
Cells; 2020 May; 9(6):. PubMed ID: 32486483
[TBL] [Abstract][Full Text] [Related]
5.
Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and prognosis potential of four gene promoter hypermethylation in prostate cancer.
Li Y; Meng L; Shi T; Ren J; Deng Q
Cell Biol Int; 2021 Jan; 45(1):117-126. PubMed ID: 32991011
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.
Haldrup C; Mundbjerg K; Vestergaard EM; Lamy P; Wild P; Schulz WA; Arsov C; Visakorpi T; Borre M; Høyer S; Orntoft TF; Sørensen KD
J Clin Oncol; 2013 Sep; 31(26):3250-8. PubMed ID: 23918943
[TBL] [Abstract][Full Text] [Related]
8. Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.
Haldrup C; Lynnerup AS; Storebjerg TM; Vang S; Wild P; Visakorpi T; Arsov C; Schulz WA; Lindberg J; Grönberg H; Egevad L; Borre M; Ørntoft TF; Høyer S; Sørensen KD
Mol Oncol; 2016 Jun; 10(6):825-37. PubMed ID: 26905753
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
[TBL] [Abstract][Full Text] [Related]
11. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
[TBL] [Abstract][Full Text] [Related]
12. Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.
Haldrup C; Pedersen AL; Øgaard N; Strand SH; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Mol Oncol; 2018 Apr; 12(4):545-560. PubMed ID: 29465788
[TBL] [Abstract][Full Text] [Related]
13. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
[TBL] [Abstract][Full Text] [Related]
14. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the clinical significance of DNA methylation in gastric cancer based on a genome-wide high-resolution array.
Fang WL; Chen MH; Huang KH; Chang SC; Lin CH; Chao Y; Lo SS; Li AF; Wu CW; Shyr YM
Clin Epigenetics; 2019 Nov; 11(1):154. PubMed ID: 31675985
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy.
Paziewska A; Dabrowska M; Goryca K; Antoniewicz A; Dobruch J; Mikula M; Jarosz D; Zapala L; Borowka A; Ostrowski J
Br J Cancer; 2014 Aug; 111(4):781-9. PubMed ID: 24937670
[TBL] [Abstract][Full Text] [Related]
17. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
[TBL] [Abstract][Full Text] [Related]
19. A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.
Castelo-Branco P; Leão R; Lipman T; Campbell B; Lee D; Price A; Zhang C; Heidari A; Stephens D; Boerno S; Coelho H; Gomes A; Domingos C; Apolonio JD; Schäfer G; Bristow RG; Schweiger MR; Hamilton R; Zlotta A; Figueiredo A; Klocker H; Sültmann H; Tabori U
Oncotarget; 2016 Sep; 7(36):57726-57736. PubMed ID: 27437772
[TBL] [Abstract][Full Text] [Related]
20. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
